County Line focuses on generic assets and specialty generic products and has a portfolio that spans multiple dosage forms with 12 marketed products in the U.S. It also has a pipeline with nine approvals and launches expected in 2016 and eight approvals in 2017.
Robert Wessman, chairman and chief executive officer of Alvogen, said, “This acquisition will provide Alvogen with further scale and additional reach in the U.S. and strengthens our portfolio and platform for future growth in our biggest market. County Line has an impressive track record, a highly efficient business model and an exciting pipeline of new products. This transaction underlines our commitment to introducing difficult-to-make products to the U.S. market and will further enhance our customer offering.”